

**CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL"**

EV 847360184 US

May 16, 2006

USPS Express Mail Label Number

Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: Sarah M. Barnett  
Sarah M. Barnett

IDS Form PTO/USPO: Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	10/600,004
Filing Date	June 18, 2003
First Named Inventor	Kelly
Art Unit	1614
Examiner Name	Delacroix-Muirheid, Cybille
Attorney Docket Number	07579.0015-01000

**U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS**

Examiner Initials	Cite No.	Document Number Number-Kind Code (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CDM		US 2005/0036962 A1	02-17-2005	Kelly et al.	
		US 2005/0049424 A1	03-03-2005	Kelly et al.	
		US 2005/0059616 A1	03-17-2005	Kelly et al.	
		US 2005/0143588 A1	06-30-2005	Heaton et al.	
		US 5,637,598	06-10-1997	Grese	
		US 6,033,714	03-07-2000	Gugger et al.	
		US 6,987,098 B2	01-17-2006	Kelly	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
CDM		EP 0 682 877 B1	04-02-2003	Nichimo Co. Ltd.		
		WO 98/21946 A1	05-28-1998	Internutria, Inc.		
		WO 98/25460 A1	06-18-1998	Zymogenetics, Inc.		
		WO 99/45923 A1	09-16-1999	Merck & Co., Inc.		
		WO 00/16759 A2	03-30-2000	Schnyder		
		WO 00/54753 A2	09-21-2000	Johnson & Johnson Consumer Companies, Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
CDM		"Novogen launches Rimostil," Press Release, 2 pages, <a href="http://www.novogen.com/news/newsPopup.cfm?id=22">http://www.novogen.com/news/newsPopup.cfm?id=22</a> (June 22, 2000).	
		BABER, R. et al. "The effect of an isoflavone dietary supplement (Rimostil™) on serum lipids, forearm bone density and endometrial thickness in post-menopausal women," <i>10th Annual Meeting of the North American Menopause Society</i> , New York, 4 pages (September 1999).	
		CASWELL, A. (Ed.) "Hypolipidaemic agents," <i>MIMS Annual</i> , 23 <sup>rd</sup> Edition, pp. 2-152 to 2-168, Tien Wah Press, Singapore (1999).	
		CHANG, Y-C. et al., "Microwave-mediated synthesis of anticarcinogenic isoflavones from soybeans," <i>J Agric Food Chem.</i> 42:1869-1871 (1994).	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/600,004
				Filing Date	June 18, 2003
				First Named Inventor	Kelly
				Art Unit	1614
				Examiner Name	Delacroix-Muirheid, Cybille
Sheet	2	of	3	Attorney Docket Number	07579.0015-01000

NON PATENT LITERATURE DOCUMENTS					
CDM		CLIFTON-BLIGH, P. et al., "The effect of isoflavones extracted from red clover (Rimostil™) on lipid and bone metabolism," <i>Menopause</i> 8(4):259-265 (2001).			
		DIXON, R. et al., "Molecular controls for isoflavonoid biosynthesis in relation to plant and human health," <i>Phytochemicals in Human Health Protection, Nutrition and Plant Defense</i> , Kluwer Academic, New York, pp. 133-159 (1999).			
		DÖREN, M. et al., "Identification and treatment of postmenopausal women at risk for the development of osteoporosis," <i>Intl. J. Clin. Pharmacology, Therapy and Toxicology</i> 30(11):431-433 (1992).			
		GOH, J.T.W. et al., "Postmenopausal endometrioma and hormonal replacement therapy," <i>Aust NZ J. Obstet. Gynaecol.</i> 32(4):384-385 (1992).			
		GOLDMAN, L. et al., "Cost and health implications of cholesterol lowering," <i>Circulation</i> 85(5):1960-1968 (1992).			
		GRAHAM, T.L., "Flavonoid and isoflavonoid distribution in developing soybean seedling tissues and in seed and root exudates," <i>Plant Physiol.</i> 95:594-603 (1991).			
		GRODSTEIN, F. et al., "Postmenopausal hormone use and cholecystectomy in a large prospective study," <i>Obstet. Gynecol.</i> 83(1):5-11 (1994).			
		HULLEY, S. et al., "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women," <i>JAMA</i> 280(7):605-613 (1998).			
		KELLY, S.A. et al., "Protein tyrosine phosphorylation mediates TNF-induced endothelial-neutrophil adhesion in vitro," <i>Am. J. Physiol. (274 Heart Circ. Physiol. 43):H513-H519</i> (1998).			
		KNIGHT, D. et al., "Phytoestrogens - a short review," <i>Maturitas</i> 22(3):167-175 (1995).			
		MAY, M.J. et al., "Effects of protein tyrosine kinase inhibitors on cytokine-induced adhesion molecule expression by human umbilical vein endothelial cells," <i>Br. J. Pharmacol.</i> 118(7):1761-1771 (1996).			
		Oenobiol Feminite Dietary Supplement, International Product Alert Vol. 16, No. 12, and product inserts, 3 pages (1999).			Translation
		PALMETSHOFER, A. et al., "α-Galactosyl epitope-mediated activation of porcine aortic endothelial cells," <i>Transplantation</i> 65(7):971-978 (1998).			
		PARFITT, K. (Ed.), <i>Martindale, The complete drug reference</i> , 32nd Edition, Pharmaceutical Press, London, Table of Contents, pp. v and vi (1999).			
		PEDERSON, T. et al., "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)," <i>The Lancet</i> 344:1383-1389 (1994).			
		SACKS, F. et al., "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels," <i>The New England Journal of Medicine</i> 335(14):1001-1009 (1996).			
		SBAROUNI, E. et al., "The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease," <i>J. Am. Coll. Cardiol.</i> 32(5): 1244-1250 (1998).			
		STAMPFER, M. et al., "A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction," <i>The New England Journal of Medicine</i> 325(6):373-381 (1991).			
		TAMURA, S. et al., "Chemical studies on 'Clover Sickness' Part I. Isolation and structural elucidation of two new isoflavonoids in red clover," <i>Agr. Biol. Chem.</i> 33(3):391-397 (1969).			
		WANG, H.J. et al., "Isoflavone content in commercial soybean foods," <i>J. Agric. Food Chem.</i> 8:1666-1673 (1994).			
✓		WEIDENBÖRNER, M., et al., "Antifungal activity of isoflavonoids in different reduced stages on <i>Rhizoctonia solani</i> and <i>Sclerotium rolfii</i> ," <i>Phytochemistry</i> 29(3):801-803 (1990).			

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/600,004
				Filing Date	June 18, 2003
				First Named Inventor	Kelly
				Art Unit	1614
				Examiner Name	Delacroix-Muirheid, Cybille
Sheet	3	of	3	Attorney Docket Number	07579.0015-01000

NON PATENT LITERATURE DOCUMENTS		
	Office Action issued in U.S. Patent No. 6,340,703 on July 9, 1999 (Attorney Docket No. 07579.0006-00000).	
	Office Action issued in U.S. Patent No. 6,340,703 on April 27, 2000 (Attorney Docket No. 07579.0006-00000).	
	Amendment and Response filed in U.S. Patent No. 6,340,703 on October 27, 2000 (Attorney Docket No. 07579.0006-00000).	
	Office Action issued in U.S. Patent No. 6,340,703 on February 9, 2001 (Attorney Docket No. 07579.0006-00000).	
	Amendment filed in U.S. Patent No. 6,340,703 on May 31, 2001 (Attorney Docket No. 07579.0006-00000).	
	Office Action issued in U.S. Patent Application No. 09/986,509 on July 23, 2002 (Attorney Docket No. 07579.0006-01000).	
	Amendment filed in U.S. Patent Application No. 09/986,509 on December 23, 2002 (Attorney Docket No. 07579.0006-01000).	
	Office Action issued in U.S. Patent Application No. 09/986,509 on February 6, 2004 (Attorney Docket No. 07579.0006-01000).	
	Amendment and Response filed in U.S. Patent Application No. 09/986,509 on August 5, 2004 (Attorney Docket No. 07579.0006-01000).	
	Office Action issued in U.S. Patent Application No. 09/986,509 on October 24, 2005 (Attorney Docket No. 07579.0006-01000).	
	Amendment and Response to Office Action filed in U.S. Patent Application No. 09/986,509 on April 24, 2006 (Attorney Docket No. 07579.0006-01000).	
	Office Action issued in U.S. Patent No. 6,599,536 on October 23, 2001 (Attorney Docket No. 07579.0013-00000).	
	Amendment filed in U.S. Patent No. 6,599,536 on March 25, 2002 (Attorney Docket No. 07579.0013-00000).	
	Office Action issued in U.S. Patent No. 6,599,536 on June 18, 2002 (Attorney Docket No. 07579.0013-00000).	
	Amendment and Response After Final filed in U.S. Patent No. 6,599,536 on December 17, 2002 (Attorney Docket No. 07579.0013-00000).	
	Notice of Allowance with Statement of Reasons issued in U.S. Patent No. 6,599,536 on April 8, 2003 (Attorney Docket No. 07579.0013-00000).	
	Preliminary Amendment filed in U.S. Patent Application No. 10/459,537 on June 12, 2003 (Attorney Docket No. 07579.0013-01000).	
	Office Action mailed in U.S. Patent Application No. 10/459,537 on December 20, 2005 (Attorney Docket No. 07579.0013-01000).	
	Office Action mailed in U.S. Patent Application No. 09/914,035 on December 18, 2002 (Attorney Docket No. 07579.0015-00000).	

Examiner Signature	<i>Cybill Delacroix-M</i>	Date Considered	6-26-06
--------------------	---------------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.